An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy

Trial Profile

An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Fulvestrant (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Atossa Genetics
  • Most Recent Events

    • 09 May 2017 According to an Atossa Genetics media release, the Institutional Review Board associated with Montefiore Medical Center (Biomedical Research Alliance of New York IRB) has approved this Phase 2 study that was recently transferred to Montefiore.
    • 09 Jan 2017 According to an Atossa Genetics media release, company anticipates completion of enrolment by August 2017.
    • 09 Jan 2017 According to an Atossa Genetics media release, company is transferring the study centre of this trial from Columbia University Medical Center Breast Cancer Programs (New York) to Montefiore Medical Center in New York.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top